Live vaccines based on attenuated microorganisms are effective in stimulating protective immune responses against a variety of pathogens. In the past, attenuated vaccine strains were derived empirically and the genetic changes responsible for attenuation were consequently unknown. This led to problems with the stability and quality control of certain live vaccines. Modern molecular genetic techniques can now be applied to construct stable, genetically defined, attenuated bacterial strains whose suitability for use as live vaccines in particular animal hosts can be assessed.
Attenuation can be achieved in a number of ways. One approach is to identify virulence determinants produced by the pathogen and construct strains, using genetic manipulation, which fail to produce those determinants. An example is the construction of strains of Vibrio cholerae, which do not express cholera enterotoxin (15, 22) . When attenuated bacterial strains are constructed, it is essential to ensure that only defined, nonreverting mutations are introduced into the genome of the pathogen. In the case of V. cholerae, mutations in the enterotoxin were initially constructed in a cloned enterotoxin gene in Escherichia coli K-12 and the mutated gene was reintroduced into V. cholerae by using genetic crosses (15, 22) .
An alternative approach to achieving attenuation is to introduce mutations into a key metabolic pathway whose function is essential for bacteria to survive and grow sufficiently in vivo to cause disease. Virulent Salmonella strains can be attenuated by introducing stable auxotrophic mutations affecting important metabolic pathways, including the prechorismate (aro mutants) and the purine biosynthetic pathways (13, 28) . Salmonella strains harboring mutations in aroA (13, 19) , aroC (7) , aroD (23) , or combinations of these mutations (7, 23) are attenuated and highly effective live oral vaccines against salmonellosis in several animal hosts (13, 19, 33) . Salmonella spp. are invasive pathogens that can enter and grow inside eucaryotic cells (9, 10) . At present, it is unknown whether aro mutants of noninvasive pathogens are attenuated.
Bordetella pertussis is the causative agent of whooping cough in humans. B. pertussis colonizes the human host by attaching to the ciliated epithelial cells lining the upper respiratory tract. There, the bacteria grow and express a variety of virulence-associated extracellular and surfacelocated proteins which induce disease symptoms. There have been reports that B. pertussis can enter eucaryotic cells, but in the human infection, B. pertussis is thought to predominently colonize the mucosal surface of the respiratory tract (2, 8, 17) . We recently reported the cloning in E. coli and sequencing of the B. pertussis aroA gene (20) . As a preliminary step towards constructing rationally attenuated strains of B. pertussis and other Bordetella species, we have constructed B. pertussis aroA mutants and tested their abilities to colonize the lungs of experimentally infected mice. The results of the study are described in this report.
MATERIALS AND METHODS Bacteria, plasmids, and growth conditions. B. pertussis CN2992F is a derivative of CN2992, the Wellcome wholecell vaccine strain, which is modulated not by increased concentrations of nicotinic acid but by temperature only (21) . A spontaneous streptomycin-resistant mutant of CN 2992F (2992FS) was used in this study. B. pertussis BP1, a streptomycin-resistant derivative of strain Tohama (14) . DNA was transferred to nylon (Pall Biodyne) filters by the method of Southern (34) . Radioactively labeled DNA probes were obtained, using nick-translation as described by Maniatis et Sera were obtained from groups of four mice by cardiac puncture and pooled. Sera were serially diluted and assayed for anti-B. pertussis immunoglobulins of the immunoglobulin G (IgG), IgM, and IgA classes, using heavy-chain-specific antibody conjugates. RESULTS Construction of B. pertussis aroA mutants. In order to construct B. pertussis aroA mutants, the cloned B. pertussis aroA gene was first inactivated in vitro. pBPTaroA52 consists of a pUC18 vector containing a 2.2-kilobase-pair PstI fragment encoding the B. pertussis aroA gene (Fig. 1 ). This plasmid can complement the aroA lesion in E. coli K-12 AB2829, allowing the strain to grow on minimal medium in the absence of aromix (20) . In order to create a single BamHI site in the aroA coding sequence, the BamHI site in the polylinker of pBPTaroA52 was removed by digestion with XbaI and EcoRI; the resultant single-stranded ends were then filled in with Klenow enzyme and blunt-end ligation, thus reconstructing the EcoRI site in the resulting plasmid, pBPTaroA53. Next, the kanamycin resistance cassette from pUC4K was cloned on a BamHI fragment into the remaining BamHI site in the aroA coding region of pBPTaroA53 to create plasmid pBPTaroA54. Inactivation of the aroA gene was checked by transforming E. coli AB2829 with pBPTaroA54; transformants could not grow on minimal medium unless it was supplemented with aromix. In preparation for returning the inactivated aroA gene to B. pertussis, the mutated aroA locus was removed from pBPTaroA54 onto the suicide shuttle vector pRTP1 as follows. pBPTaroA54 was cleaved to completion with EcoRI and then partially with HindlIl. A 3.6-kilobase-pair EcoRIHindlIl fragment containing the cloned DNA from pBPTaroA54, including the Kmr cassette, was gel purified and ligated into pRTP1 previously cleaved with EcoRI and HindIII. E. coli transformants harboring the resultant plasmid were selected for resistance to Apr and Kmr. The resulting plasmid was called pBPTaroA55.
pRTP1 is mobilizable by sequences derived from RP4 on the chromosome of E. coli SM10 and does not replicate in B. pertussis because of the absence of the pir gene product, carried in SM10 on a lysogenic bacteriophage. Furthermore, pRTP1 encodes the S12 allele which confers streptomycin sensitivity on otherwise streptomycin-resistant bacterial strains. E. coli SM1O(pBPTaroA55) was plate mated with B.
pertussis BP1 or CN2992FS, and transconjugants were selected with CW blood agar plates containing streptomycin and kanamycin as selective antibiotics.
Any B. pertussis colonies appearing on the selective plates should be aroA mutants, since Kmr should only be expressed if the wild-type aroA allele is replaced on the chromosome by the mutated aroA gene. This recombination may take place by two general mechanisms, one involving crossover between homologous structures of B. pertussis DNA at a single site within or flanking the aroA gene (which would result in insertion of the entire recombinant plasmid) and the other involving two regions separated by the site of the kanamycin resistance cassette insert (which would result in replacement of only the aroA allele) with no vector integration. Because of the S12 allele on pRTP1, streptomycin in the medium selects against the single crossovers and thus selects against vector integration.
Kmr and Smr B. pertussis transconjugants were purified by being replated on CW medium with or without aromix. Purified colonies grew very slowly or not at all on medium without aromix but grew at a rate similar to that of wild-type B. pertussis on medium containing aromix, giving rise to colonies which were similar in size to the parent strains. Some of these colonies were subcultured on CW blood agar plates and, after 72 h, the growth was washed off and inoculated into 200 ml of SS medium in a 500-ml conical flask and incubated at 37°C in an orbital shaker. These isolates could grow in the SS medium containing aromix but not in nonsupplemented medium.
After some matings with BP1 as a recipient, some small (Fig. 1) . The probe hybridized to a 3.5-kilobase NcoI fragment in the parental strain and a 4.8-kilobase NcoI fragment in the aroA mutant. The increased size of the fragment corresponds to the insertion of the kanamycin resistance gene (Fig. 1) . This was confirmed by using digestion with other restriction endonucleases (results not shown). BP1 aroA produced an identical hybridization pattern.
Survival of B. pertussis aroA mutants in vivo. The B. pertussis parent strains and aroA mutants were assessed for their abilities to colonize the lungs of mice. Adult outbred NIH/S mice were exposed to an aerosol generated from a suspension of between 2 x 109 and 4 x 109 CFU of B. pertussis bacteria per ml. This reproducibly led to seeding of the mouse lungs with 103 to 104 B. pertussis organisms.
Survival of viable bacteria was followed by performing viable counts on homogenates of lungs removed from groups of four mice at intervals after the mice were exposed to aerosol. The results obtained with CN2992FS and CN2992FS aroA are shown in Fig. 2 . BP1 and BP1 aroA behaved in a similar manner (results not shown). The parental strain, after an initial drop in numbers during the first day, multiplied to reach 105 to 106 CFU in the lung 11 days postchallenge (Fig. 2) . Thereafter, the counts decreased gradually, but B. pertussis could still be detected in the lungs 32 days after infection. CN2992FS aroA did not efficiently colonize the mouse lung. The numbers of CN2992FS aroA bacteria present decreased daily after aerosol presentation until bacteria were cleared from the lungs between days 5 and 8 (Fig. 2) shown). To enhance the protection observed, mice were given multiple doses of the attenuated strain. Mice were ,immunized three times with intervals of 3 days between the first and second doses and 4 days between the second and third doses. The means of the doses received, calculated by using groups of four mice, were 2.6 x 103 CFU in the first dose, 8 .6 x 10 CFU in the second dose, and 1.2 x 104 CFU in the third dose. The CN2992FS aroA strain was not detected in the lungs of mice 11 days after the final inoculation. The immunized and control mice were challenged with CN2992FS 24 days after the third dose was administered.
The immunized mice cleared the challenge strain rapidly. At 3 days postchallenge, only one of the four mice examined had B. pertussis present in its lungs, and all subsequent mice examined were free from B. pertussis (Fig. 3) . The control mice remained colonized for at least 21 days after being exposed to CN2992FS. It can also be seen from the control group that CN2992FS did not grow to levels as high as those in younger mice and was cleared earlier than it was in younger mice. Aerosol immunization with three doses of a B. pertussis aroA mutant clearly prevents subsequent normal colonization of the lungs of mice by wild-type organisms.
Serum antibody response to B. pertussis. Sera were collected from aerosol-immunized and control mice at intervals after respiratory challenge with 2992FS and assayed for B. pertussis antibodies by ELISA, using whole B. pertussis as antigen. A low level of anti-B. pertussis antibodies was detected in the sera of immunized, but not control, mice 10 days before challenge (Fig. 4) . Anti-pertussis immunoglobulins appeared rapidly in the sera of immunized mice and reached high levels by the second week after challenge (Fig.  4) . The anti-B. pertussis antibodies remained high for several weeks and then decreased, returning to low levels by day 46 postchallenge (Fig. 4) . The rise in pertussis-specific serum antibodies in immunized mice correlates with the disappearance of the challenge organism from the lungs. In contrast, significant levels of anti-pertussis antibodies were only detected in the sera of control mice 46 days after challenge, which is 25 days after B. pertussis was last isolated from their lungs (Fig. 4) The B. pertussis aroA mutants were rapidly cleared from the lungs of infected mice. This contrasts with the behavior of Salmonella typhimurium aroA mutants, which can persist for several weeks in the livers and spleens of mice after they are orally infected (13, 19) . This could be a reflection of the animal infection systems used or differences in physiological properties between Salmonella and Bordetella species. Salmonella spp. can enter and replicate within macrophages and eucaryotic cells, whereas B. pertussis is predominantly an extracellular pathogen (2, 8, 17 (1, 6, 24, 29) . However, the importance of the local secretory immune system in controlling lung infections should not be overlooked.
The results described above and those of others show that serum anti-B. pertussis immunoglobulins only rise to significant levels in mice recovering from sublethal respiratory infection some weeks after the infection has been terminated. This indicates that local factors are responsible for clearing bacteria from the lungs of nonimmune mice. Geller and Pittman (11) detected B. pertussis-specific immunoglobulins, predominantly IgA, in the tracheobronchial washings of intranasally infected mice 15 days after infection. The only change in the serum immunoglobulin profile was a change in serum IgA (the specificity of which was not determined) 30 days after the initiation of infection. We are currently investigating the local immune response in the murine lung after administration of B. pertussis aroA.
Preliminary studies using convalescent sera of immunized and nonimmunized mice suggest that the antibody response is directed against several polypeptides (our unpublished results). The availability of purified B. pertussis antigens should make characterization of humoral and cellular immune responses to B. pertussis simpler. 
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The mouse aerosol challenge system is an unsatisfactory model for human whooping cough. We have never observed mouse-to-mouse lung infection with B. pertussis, although this is common with Bordetella bronchiseptica, which causes serious infections in a variety of animal species. We have recently constructed B. bronchiseptica aroA mutants, using methods similar to those described in this report. These will be evaluated in the appropriate model systems to see whether other Bordetella species, better adapted to survival in their hosts, can be attenuated by using aroA mutations.
Salmonella aroA mutants have been used to deliver heterologous antigens to the mammalian immune system. The heterologous antigens have been derived from bacteria (3, 19) , viruses (37) , and parasites (30) . After the attenuated Salmonella species expressing the heterologous antigen have been delivered orally, both systemic and secretory antibody responses have been detected. The attenuated B. pertussis aroA strains described in this report could be used to deliver non-Bordetella antigens to the respiratory tract mucosal surface. We are currently investigating this possibility.
